sequencing of agents in lr-mds
Published 7 months ago • 37 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:32
genomic sequencing as a driver of advancements in pediatric hematology
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:16
current therapeutic combinations and optimizing the sequencing of drugs in lr-mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
3:10
the role of ngs in mds diagnosis
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
6:32
a phase i trial of dsp-5336, a novel menin inhibitor, in the treatment of aml
-
5:22
magrolimab azacitidine in mds and aml
-
2:47
molecular background studies to aid diagnosis and treatment of mds
-
1:01
evolving role of next-generation sequencing in mds
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:32
next-generation sequencing for low-risk mds
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
6:22
integrated sequencing in aml/mds reveals prognostic constellations
-
3:37
progress in the categorization and treatment of lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
1:34
managing adverse events with novel therapies in lower-risk mds
-
1:03
the growing importance of single-cell rna sequencing in hematology
-
3:44
erythropoiesis-stimulating agents in mds
-
2:43
novel therapies in the future of mds treatment